Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
iVeena logo — Lead programs comprise of novel proprietary eye drops; IVMED...

iVeena

Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and IVMED-85 for myopia

Founded 2006 United States Salt Lake City, United States 6 employees Venture round Total: $4.27M Biotechnology, Life Sciences +1

General Information

Company Name iVeena
Founded Year 2006
Location United States Salt Lake City, United States
Employees 6
Industries Biotechnology, Life Sciences, Medical Devices
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with iVeena. To contact iVeena, visit iveenamed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About iVeena

is a biotechnology startup founded in 2006 and headquartered in the United States. The company's slogan, "Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and IVMED-85 for myopia," highlights its focus on developing non-surgical, non-invasive, and pharmacologic innovations in the field of ophthalmology. Their last investment was a $2.13M Venture Round investment on 08 July 2020. iVeena is currently in the clinical stage and is dedicated to addressing unmet needs in corneal diseases and myopic conditions. Their lead programs consist of novel proprietary products, including IVMED-80 for keratoconus and IVMED-85 for myopia. Overall, iVeena’s innovative approach to ophthalmology and focus on disease-modifying interventions position it as a promising player in the biotechnology industry.

Taxonomy: ophthalmology, clinical stage, non-surgical, non-invasive, pharmacologic innovation, disease modifying intervention, keratoconus, myopia, proprietary eye drops, IVMED-80, IVMED-85, corneal diseases, myopic conditions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.13M -
08 Jul 2020
Series B Undisclosed 1
Mountain Pacific Partners
Mountain Pacific Partners
01 Jan 2019
Grant $224.99K 1
National Science Foundation
National Science Foundation
10 Jul 2017
Seed Round $600.00K 2
Park City Angels
Park City Angels, PC Squared, LLC
18 Dec 2015
Seed Round $1.30M 2
Park City Angels
Park City Angels, Technology Venture Corporation
25 Sep 2015
Seed Round $10.00K -
30 Apr 2015

iVeena Alternatives & Competitors

View All Alternatives
iVeena vs
Epion Therapeutics
Epion Therapeutics United States

A clinical-stage company developing a minimally-invasive treatment for keratoconus

Series A
12 employees
Biotechnology, Health Care
iVeena vs
BAROnova
BAROnova

A clinical-stage medical-device company innovating non-surgical, non-pharmacologic solutions for wei...

Debt Financing
4 employees
Biotechnology, Health Care
iVeena vs
Cognito Therapeutics, Inc.
Cognito Therapeutics, Inc. United States

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative disease...

Series B
53 employees
Biotechnology, Health Care
View all alternatives

FAQ About iVeena

Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and IVMED-85 for myopia
iVeena was founded in 2006.
iVeena is headquartered in Salt Lake City, United States.
iVeena operates in Biotechnology, Life Sciences and Medical Devices. Its work centres on ophthalmology, clinical stage, non-surgical and non-invasive.
iVeena has approximately 6 employees.
iVeena has completed 6 funding rounds, raising a total of $4.27M. The latest funding stage is Venture round.
Top alternatives and competitors to iVeena include Epion Therapeutics, BAROnova, Cognito Therapeutics, Inc., Salutaris Medical Devices, CytoPherx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iVeena and Epion Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iVeena, https://bouncewatch.com/company/iveena, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes